Job Opportunity: Postdoc, Division of Hematology/Oncology, VICC

Kate Stuart
April 3, 2014
The laboratory of Carlos L. Arteaga, MD in the Breast Cancer Program of the Vanderbilt-Ingram Comprehensive Cancer Center is recruiting post-doctoral research fellows.
 
Interested applicants should send updated CV and list of references to carlos.arteaga@vanderbilt.edu
 
Projects include:
•Discovery of mechanisms of resistance to antiestrogen therapy in breast cancer
•Development of transgenic mouse models of basal-like breast cancer
•Genomic profiling of drug-resistant ER+ and triple negative breast cancer
•Discovery of rational combinations of targeted therapies in breast cancer (focus on PI3K/AKT, ERBB receptors, TGF, ER, CDK4)
 
Methods include gain-of-function kinase screens, next gen sequencing, RNAseq, mass spectrometry, RNAi screens, functional small animal imaging, molecular profiling and discovery using primary tumors from patients in clinical trials with targeted therapies, and studies with cell lines and xenografts using conditional shRNAs and targeted therapies in clinical development in vitro and in vivo.
 
Recent relevant publications that apply to these topics include:
Miller TW, Fox EM, Balko JM, Ghazoui A, Dunbier A, Anderson H, Dowsett M,
Jiang A, Smith RA, Sánchez V, Maira S-M, Manning HC, González-Angulo AM,
Mills GB, Higham C, Ye F, Miller WR, Shyr Y, Arteaga CL. ER-dependent E2F
transcription can mediate resistance to estrogen deprivation in human breast
cancer. Cancer Discovery 1:338-51, 2011
 
Chakrabarty A, Sánchez V, Kuba MG, Rinehart C, Arteaga CL. Feedback
upregulation of HER3 (ErbB3) expression and activity attenuates antitumor
action of phosphatidylinositol-3 kinase pathway inhibitors. Proc. Natl. Acad.
Sci. USA 109:2718-23, 2012
 
Arteaga CL, Baselga J. Impact of Genomics in Personalized Cancer Medicine.
Clin. Cancer Res. 18:612-8, 2012
 
Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME,
Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K,
González-Angulo AM, Mills GB, Pinto JA, Gomez HL, Arteaga CL. Profiling of
residual breast cancers after neoadjuvant chemotherapy identifies DUSP4
deficiency as a mechanism of drug resistance. Nature Med. 18:1052-9, 2012
 
Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C, Sánchez
V, Jee D, Polyak K, Prat A, Perou CM, Arteaga CL, Cook RS. The receptor
tyrosine kinase ErbB3 maintains the balance between luminal and basal breast
epithelium. Proc. Natl. Acad. Sci. USA 109:221-6, 2012
 
Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V,
Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Conditional loss of ErbB3
delays mammary gland hyperplasia induced by mutant PIK3CA without affecting
mammary tumor latency, gene expression or signaling. Cancer Res. 73:4075-85,
2013
 
Bhola N, Balko JM, Dugger TC, Kuba MG, Stanford J, Cook RS, Arteaga CL. TGFβ
inhibition enhances chemotherapy action against triple-negative breast
cancer. J. Clin. Invest. 123:1348-58, 2013
 
Fox EM, Kuba MG, Miller TW, Davies BR, Arteaga CL. Autocrine IGF/insulin
receptor axis compensates for inhibition of AKT in ER positive breast cancer
cells with acquired resistance to estrogen deprivation. Breast Cancer Res.
2013 Jul 11; 15(4):R55 [Epub ahead of print]
 
Balko JM, Stricker TP, Arteaga CL. The genomic map of breast cancer: Which
roads lead to better targeted therapies? Breast Cancer Res. 2013 Jul
31;15(4):209 [Epub ahead of print]
 
Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng
Q, Wallweber J, DeFazio-Eli L, Arteaga CL. Combination of antibody that
blocks ligand-independent HER3 dimerization and a p110 inhibitor potently
block PI3K signaling and growth of HER2-overexpressing breast cancers. Cancer
Res. 73:6013-23, 2013
 
Hanker AB, Pfefferle A, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR,
Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Mutant PIK3CA accelerates
HER2-driven transgenic mammary tumors and induces resistance to combinations
of anti-HER2 therapies. Proc. Natl. Acad. Sci. USA 110:14372-7, 2013
 
Balko JM, Schwarz LJ, Bhola N, Kurupi R, Owens P, Miller TW, Gómez H, Cook
RS, Arteaga CL. Activation of MAPK pathways via DUSP4 loss promotes cancer
stem cell-like phenotypes in basal-like breast cancer. Cancer Res.
73:5346-58, 2013
 
Balko JM, Giltnane JM, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME,
Kuba MG, Sánchez V, Pinto JA, Doimi F, Gómez H, Goga A, Lehmann B, Bauer J,
Pietenpol JA, Stephens PA, Cronin M, Miller VA, Yelensky R, Wang K, Palmer G,
Arteaga CL. Molecular profiling of drug-resistant tumor cells remaining in
the breast after neoadjuvant chemotherapy of triple-negative breast cancers
identifies actionable therapeutic targets. Cancer Discov. 4:232-245, 2014
 
Mayer IA, Abramson VG, Isakoff SJ, Forero-Torres A, Balko JM, Kuba MG,
Sanders ME, Yap J, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL.
Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With
Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor
Receptor 2-Negative Metastatic Breast Cancer. J Clin. Oncol. (In press), 2014
 
Arteaga CL, Engelman JA. ERBB receptors: From oncogene discovery to basic
science to mechanism-based cancer therapeutics. Cancer Cell (In press), 2014